All type of patients : 3 trials - Weitz (edoxaban phase 2) - ENGAGE-AF TIMI 48 High dose - phase 2 edoxaban
| edoxaban vs warfarin standard dose | No demonstrated result | |
| edoxaban high dose vs warfarin standard dose | No demonstrated result Gastrointestinal major bleeding by 23% (harmful effect) suggested Lifethreatening major bleeding by 49% (not demonstrated) suggested major or clinically relevant non-major bleeding by 14% (not demonstrated) suggested Major bleeding by 20% (not demonstrated) suggested Haemmorhagic stroke by 53% (not demonstrated) suggested Fatal bleeding by 45% (not demonstrated) suggested Cardiovascular death by 14% (not demonstrated) |
All type of patients : 5 trials - STARS J-V - DU176b-B-J302 - DU176b-B-J303 - DU176b-B-J304 - DU176b-04
| edoxaban vs enoxaparin | No demonstrated result | |
| edoxaban vs enoxaparin (short duration) | No demonstrated result suggested major VTE (fatal and non fatal DVT,PE) by 66% (not demonstrated) suggested asymptomatic DVT by 62% (not demonstrated) suggested distal DVT by 64% (not demonstrated) | |
| edoxaban vs placebo | No demonstrated result |
All types of patients: 1 trials - Edoxaban Hokusai VTE
| heparin/edoxaban vs heparin/VKA | No demonstrated result suggested major or clinically relevant non-major bleeding by 17% (not demonstrated) suggested Bleeding by 15% (not demonstrated) |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
